Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Gamida Cell's StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study 

 

Gamida Cell's StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
February 4, 2013 - (Gamida Cell) - "Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma." Read Full Press Release

 

Posted on 14-Feb-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: